Daniel Tak Mao Chan obtained his MBBS, MD, and DSc degrees from the University of Hong Kong (HKU). He became Professor at the HKU Department of Medicine in 1999, then Chair Professor in 2005, Yu Chair of Nephrology in 2008, and Yu Chiu Kwong Chair of Medicine in 2011. He has been Chief of Nephrology of HKWC Hospitals since 2010.
His research themes include lupus nephritis and viral hepatitis in patients with kidney diseases. His seminal works established mycophenolate as standard-of-care for the treatment of lupus nephritis globally, and strategies to prevent HBV and HCV complications in patients with kidney disease, both resulting in significantly improved patient outcomes. Translational studies from his laboratory have increased the understanding of pathogenic mechanisms in renal inflammation and fibrosis. His publications have appeared in New England Journal of Medicine, Kidney International, Journal of American Society of Nephrology, Arthritis Rheumatology, Nature Review Nephrology, Gastroenterology, and Hepatology. He is Lead Author for the Lupus Nephritis chapter in the 2021 KDIGO Clinical Management Guideline for Glomerulonephritis, and author of chapters on hepatitis B management in kidney disease patients in UpToDate.
He has served as Associate Dean, Senate member, and University Selection & Promotion Committee member at HKU, and is currently Member of the HKU Council. He also served as President of Asian Pacific Society of Nephrology (APSN), President of Hong Kong Society of Transplantation, Executive Committee member of Asian Society of Transplantation, HK West Cluster Hospitals Department of Medicine Chief of Clinical Service, Chairman of Hong Kong Hospital Authority Coordinating Committee in Internal Medicine, and Council member of International Society of Nephrology (ISN). Since 2016 he is Vice-President and Chairman of Education & Accreditation Committee of Hong Kong College of Physicians. He is serving on the Biology & Medicine panel of Hong Kong Research Grants Council Joint Research Scheme, and as grant reviewer for research funding institutes locally and overseas. He established the first (and only) ABO-incompatible kidney transplant program in Hong Kong at Queen Mary Hospital in 2017. He received the HKU Outstanding Researcher Award in 2006, and the APSN Kenzo Oshima Award in 2014.
